US FDA’s ODA committee recommends approval of AstraZeneca’s Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer: Cambridge, UK Monday, May 4, 2026, 17:00 Hr ...
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with ...
Investigators proposed criteria to define procedural success after minimally invasive surgical treatments (MISTs) for benign prostatic obstruction (BPO).
In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...
ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...
Bayer received an FDA Untitled Letter this week for its prostate cancer drug Nubeqa, shortly after it launched a lawsuit ...
AstraZeneca (AZN) stock drops after FDA advisors reject breast cancer drug camizestrant 6-3, while prostate treatment Truqap ...
Total Revenue -- $164.9 million, up from $157.2 million the previous year; reflects increasing prescriptions and patient volume. Prescription Trends -- Record levels of new prescriptions, new patient ...
Men who drink six cups of coffee a day showed a lower risk of developing a deadly type of prostate cancer compared with nondrinkers, a large U.S. study suggests. The study by researchers at the ...
MedPage Today on MSN
FDA Staff Raises Concerns on Two Cancer Drug Applications
The Oncologic Drugs Advisory Committee will meet for the first time in 9 months ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back ...
Cancer specialists had the lowest rate of malpractice lawsuits among all specialties included in an American Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results